| Not Yet Recruiting | Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and NCT07372079 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer NCT07132008 | First Affiliated Hospital of Guangxi Medical University | Phase 3 |
| Not Yet Recruiting | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer NCT07159217 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bla NCT06960577 | AstraZeneca | Phase 3 |
| Recruiting | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stag NCT07034326 | Kong Fanming | Phase 2 / Phase 3 |
| Recruiting | Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma NCT06446154 | Sun Yat-sen University | Phase 2 |
| Recruiting | Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Ga NCT06576921 | Xijing Hospital | Phase 2 |
| Recruiting | The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer NCT06975384 | Second Xiangya Hospital of Central South University | — |
| Recruiting | A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immun NCT06647134 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC NCT06632106 | First Hospital of China Medical University | — |
| Unknown | Fertility and Pregnancy After Avelumab Treatment NCT06242522 | Hospices Civils de Lyon | N/A |
| Not Yet Recruiting | Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcino NCT06279403 | RenJi Hospital | Phase 2 |
| Active Not Recruiting | Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer NCT06124378 | First Affiliated Hospital of Guangxi Medical University | Phase 2 |
| Not Yet Recruiting | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma NCT05898256 | Guangxi Medical University | Phase 1 / Phase 2 |
| Recruiting | Observational Cohort Study of Chronic Viral Infection in the Central Nervous System NCT07512518 | Peking Union Medical College Hospital | — |
| Unknown | Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepa NCT06040177 | First Affiliated Hospital of Guangxi Medical University | Phase 1 / Phase 2 |
| Unknown | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies NCT05487443 | First People's Hospital of Hangzhou | Phase 2 / Phase 3 |
| Recruiting | Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer NCT05260606 | Samsung Medical Center | — |
| Unknown | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer NCT05310383 | Lei Li | Phase 2 |
| Unknown | PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer NCT05310305 | Lei Li | — |
| Completed | Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy NCT05273255 | Michael Scharl | N/A |
| Unknown | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial NCT05290935 | Lei Li | Phase 2 |
| Active Not Recruiting | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population NCT05863052 | University of Oklahoma | — |
| Unknown | irAE Prediction of Anti-PD-1/L1 in Lung Cancer NCT05288569 | Peking Union Medical College Hospital | — |
| Recruiting | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors a NCT04572451 | Yana Najjar | Phase 1 |
| Unknown | A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patient NCT05123287 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immun NCT05813418 | Centre Hospitalier Universitaire, Amiens | N/A |
| Active Not Recruiting | Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced C NCT04808817 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoin NCT04826406 | Hunan Cancer Hospital | Phase 2 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Unknown | Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors NCT05349058 | Flinders University | — |
| Completed | Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immu NCT06629714 | Anhui Medical University | — |
| Recruiting | The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG) NCT05477979 | Second Xiangya Hospital of Central South University | — |
| Recruiting | A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver I NCT06402981 | Zhejiang University | — |
| Completed | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology NCT03948724 | Institut Cancerologie de l'Ouest | N/A |